Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;13(2):275-282.
doi: 10.34172/apb.2023.030. Epub 2022 Jan 8.

Chitosan and Its Structural Modifications for siRNA Delivery

Mona Y Al-Absi  1 , Anna Eleonora Caprifico  1 , Gianpiero Calabrese  1
Affiliations
Review

Chitosan and Its Structural Modifications for siRNA Delivery

Mona Y Al-Absi et al. Adv Pharm Bull. 2023 Mar.

Abstract

The use of RNA interference mechanism and small interfering RNA (siRNA) in cancer gene therapy is a very promising approach. However, the success of gene silencing is underpinned by the efficient delivery of intact siRNA into the targeted cell. Nowadays, chitosan is one of the most widely studied non-viral vectors for siRNA delivery, since it is a biodegradable, biocompatible and positively charged polymer able to bind to the negatively charged siRNA forming nanoparticles (NPs) that will act as siRNA delivery system. However, chitosan shows several limitations such as low transfection efficiency and low solubility at physiological pH. Therefore, a variety of chemical and non-chemical structural modifications of chitosan were investigated in the attempt to develop a chitosan derivative showing the features of an ideal siRNA carrier. In this review, the most recently proposed chemical modifications of chitosan are outlined. The type of modification, chemical structure, physicochemical properties, siRNA binding affinity and complexation efficiency of the modified chitosan are discussed. Moreover, the resulting NPs characteristics, cellular uptake, serum stability, cytotoxicity and gene transfection efficiency in vitro and/or in vivo are described and compared to the unmodified chitosan. Finally, a critical analysis of a selection of modifications is included, highlighting the most promising ones for this purpose in the future.

Keywords: Chitosan; Chitosan derivatives; Gene therapy; Nanoparticles; Tumour; siRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
See this image and copyright information in PMC

References

    1. Seyhan AA. RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet. 2011;130(5):583–605. doi: 10.1007/s00439-011-0995-8. - DOI - PubMed
    1. Chuan D, Jin T, Fan R, Zhou L, Guo G. Chitosan for gene delivery: methods for improvement and applications. Adv Colloid Interface Sci. 2019;268:25–38. doi: 10.1016/j.cis.2019.03.007. - DOI - PubMed
    1. Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 2016;4(7):35–50. doi: 10.14304/surya.jpr.v4n7.5. - DOI - PMC - PubMed
    1. Mahmoudpour M, Ding S, Lyu Z, Ebrahimi G, Du D, Ezzati Nazhad Dolatabadi J, et al. Aptamer functionalized nanomaterials for biomedical applications: recent advances and new horizons. Nano Today. 2021;39:101177. doi: 10.1016/j.nantod.2021.101177. - DOI
    1. Schiffelers RM, Mastrobattista E. Oligonucleotides. In: Crommelin DJ, Sindelar RD, Meibohm B, eds. Pharmaceutical Biotechnology: Fundamentals and Applications. 3rd ed. New York: Informa Healthcare USA, Inc; 2008. p. 211-24. 10.3109/9781420044386. - DOI

LinkOut - more resources